Shotlee LogoShotlee
Blog
Download on theApp Store
Become aBeta Tester
Skip to main content
Ozempic, a Diabetes Medication, Slated for India Launch This Month - Featured image
Health

Ozempic, a Diabetes Medication, Slated for India Launch This Month

Novo Nordisk is set to introduce Ozempic in India, complementing their existing semaglutide product line. This launch occurs amidst strong competition from Eli Lilly's Mounjaro. The new medication may also be prescribed for other health conditions.

Shotlee·December 4, 2025·Updated Jan 27, 2026·1 min read
Share:

Diabetes Drug Ozempic Coming to India This Month

Novo Nordisk's semaglutide portfolio in India will be completed with the launch of Ozempic, providing therapeutic options for both diabetes and obesity. This introduction follows increasing competition from Eli Lilly's Mounjaro, a US rival approved for both diabetes and weight management. Pharmarack data indicates that Lilly sold 262,000 doses of Mounjaro in October, compared to Novo's Wegovy with 26,000 doses.

Novo Nordisk already maintains a significant presence in the diabetes market in India through its Rybelsus semaglutide tablets and other offerings. According to Vishal Manchanda, an analyst from Systematix Institutional Equities, "Novo is well-positioned to promote Ozempic due to its established brand recognition in diabetes treatment."

Track your medication journey

Join thousands using Shotlee to track GLP-1 medications.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Become aBeta Tester

Furthermore, Manchanda suggested that "Ozempic may potentially be prescribed for individuals experiencing infertility or sleep apnea, and for those seeking weight reduction." Health tracking apps like Shotlee can help monitor any side effects from new medications.

Original source: NewsBytes

View original article →
#Ozempic#diabetes#India#Novo Nordisk#Mounjaro#semaglutide#weight loss
  1. Home
  2. Blog
  3. Ozempic, a Diabetes Medication, Slated for India Launch This Month

Related Articles

New Diet Lowers Methionine & Cysteine to Trigger Fat Burning Without Exercise
Metabolic Health

New Diet Lowers Methionine & Cysteine to Trigger Fat Burning Without Exercise

Lab mice shed pounds when key amino acids—methionine and cysteine—were cut from their diet, igniting fat burning without exercise. A University of Southern Denmark study shows this diet-induced thermogenesis boosted calorie burn by 20%, nearly matching constant cold exposure. This could redefine obesity treatments beyond GLP-1 drugs.

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations
GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds
GLP-1 Medications

SNAC in Ozempic and Wegovy Tablets Raises Gut Health Questions, Study Finds

New research uncovers potential effects of SNAC—the hidden ingredient enabling Ozempic and Wegovy tablets—on gut health. In a 21-day animal study, repeated exposure led to shifts in harmful gut bacteria, elevated inflammation, and depleted cognitive proteins. While not proving harm in humans, findings urge caution as oral semaglutide use surges.

Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Get Started

Resources

  • Health Blog
  • Support Center
  • System Status

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with ♥ for the community